Abstract
Introduction
Polypharmacy and high-risk prescribing are highly prevalent in the older population. One of the core strategies how to reduce these negative phenomena are pharmacist-or physician-led medication reviews, and the process of deprescribing. Deprescribing has been defined as '…withdrawal of inappropriate medication, supervised by a healthcare professional with the goal of managing polypharmacy and improving older patient safety and health outcomes.' 1 Many different tools have been developed for deprescribing [e.g. different geriatric risk scores, geriatric tools enabling identification of anticholinergic and sedative drug burden, implicit prescribing algorithms or explicit criteria of potentially inappropriate medications
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(so called PIMs)]. 2 The latter are older and simpler tools, now more used in clinical practice and research.
The first explicit criteria of PIMs have been published already 20 years ago (Beers 1991 criteria) 3 and the newest, extensive lists of PIMs applied in international research are (a) the American Geriatrics Society Beers criteria (AGS Beers criteria, with the previous version published in 2015, 4 now newly updated in January 2019), 5 (b) the STOPP/START 2015 criteria (version 2), 6 and (c) the European Union (EU)(7)-PIM list from 2015. 7 While the EU (7)-PIM list and Section 1 of the AGS Beers criteria state PIMs mostly disregard clinical conditions of inappropriateness and may be applied in regulatory studies, the application of STOPP/START criteria require clinical information on results of patients' clinical assessments and lab tests and these criteria are specifically designed for identification of PIMs in clinical practice. [4] [5] [6] [7] Of the three above-stated criteria, the EU(7)-PIM list is the first multicentric European tool developed by experts from seven EU countries, namely from Estonia, Netherlands, Finland, Spain, France, Sweden and Denmark. 7 However, in national research and clinical practice, mostly higher specificity of national tools have been confirmed, for example, of Laroche's criteria in France, 8 NORGEP 9 and NORGEP-NH criteria in Norway, 10 the PRISCUS list in Germany, 11 and McLeod's 12 and Rancourt's criteria in Canada, 13 etc. These tools have been developed for specific national studies by excluding PIMs not approved on country-specific pharmaceutical markets and by inserting 'new PIMs' available only in a specific country. For these reasons, applicability of national criteria in the international context is limited.
Sufficient numbers of studies confirmed serious negative outcomes of PIMs, for example, increase in the prevalence of geriatric symptoms and syndromes (drug-related bradycardias, renal insufficiency, cognitive impairment, deliria, drug-related malnutrition, falls, etc.), increase in number and length of hospitalizations, worsening of geriatric frailty, higher utilization of healthcare services and costs, and also increase in mortality in several studies. [14] [15] [16] [17] [18] [19] However, despite much evidence on negative outcomes, prescribing of PIMs is still high in the older population and varies significantly across different settings of care, facilities, regions, and countries. As confirmed by two systematic reviews, the weighted point prevalence of PIM use in European studies was 49.0% in institutional care and 22.6% in community-residing older adults. 20, 21 The US study by Jiron et al. described the decrease in PIM prevalence from 64.9% to 56.6% between 1997 and 2012, respectively. 22 However, the Irish study found the increase in the prevalence from 32.6% to 37.3% in the same period. 23 It is well known that PIM prescribing is also strongly influenced by prescribing habits, different perceptions of physicians on inappropriateness of PIMs, different country-specific recommendations, guidelines and regulations. 31 .6% in Norway to 70.9% in Italy. In the majority of European countries, approval rates of PIMs were around 50% (e.g. 48 .1% in the Netherlands, 50 .6% in Iceland, 51.9% in Denmark and Czech Republic (CZ), and 55.7% in Finland and United Kingdom), but these PIM lists and the prevalence of prescribing of individual PIMs widely differed. For example, pentoxifylline was overprescribed to 20% of older adults in the CZ (and broadly advertised) while in other EU countries, this PIM was not approved for clinical use (e.g. in Denmark, Iceland, Netherlands, Norway and the United Kingdom) or was used rarely (prevalence of 1.1% in Finland and 1.2% in Italy). 24 Similar discrepancies have also been found for many other PIMs. These findings raised attention to regulatory issues related to PIM use in our research.
In the European Union, protection of public health and the high quality, effective and safe medicinal products should be guaranteed by the European regulatory system for medicines within the EU. This system is represented by the network of medicines' regulatory authorities from 31 European Economic Area member states, the European Commission and the European Medicines Agency (EMA). 25 All medicines in the EU must be authorized before being available for patients and there are different routes for authorizing medicinal products. 26 Such marketing authorization is valid for entire EU market and all member states. 27 Some specific medicines (e.g. most innovative medicines) fall into the scope of mandatory centralized authorization procedure. 25 However, there are also other types of authorization procedures, mainly the decentralized procedure, mutual-recognition and national authorization procedure. The decentralized procedure can be used in situation when a medicinal product is not authorized in any of the EU countries yet and the company applies for the authorization in more than one EU member state at the same time. The mutual-recognition procedure is represented by the situation when a medicinal product is authorized in only one EU member state and the company applies for authorization in other EU countries (this type of procedure allows EU member states to rely on each other's scientific assessments) and the national procedure represents the authorization procedure unique to every EU member state. [25] [26] [27] Most of the medicines available in the EU (and particularly, older medicines like PIMs mostly are) were authorized for clinical use at the national level. They were mostly authorized before EMA's creation and were not in the scope of the centralized authorization procedure. For this reason, approval rates, recommendations and preferences for the use of PIMs highly differ in different EU countries. Different approval rates of PIMs and regulations [e.g. prescribing limits for individual PIMs, over-the-counter (OTC) availability, etc.] also significantly influence the applicability of different PIM criteria in research and clinical practice. 24, 28 Because the EU(7)-PIM list becomes one of the preferred tools for clinical practice and research in European studies, the aim of our study was to describe (using quantitative and qualitative analyses) the approval rates and selected regulatory aspects (e.g. EMA's authorization, actual availability on the pharmaceutical market, and availability only on prescription or as an OTC medication) for PIMs stated on the EU (7) 
Explicit criteria of PIMs
The list of PIMs used in our research was created from two explicit criteria of PIMs in the older population published in the USA and Europe in 2015. These were the AGS 2015 Beers criteria (Section 1), 4 which represented the latest Beers criteria update at the time of our study (in January 2019, a new update of AGS Beers 2019 was released). 5 These criteria were developed by experts of the AGS. Also, the EU(7)-PIM list published by Renom-Guiteras and colleagues 7 was used in our analyses as the first international European tool developed for international studies. Both of these criteria [EU(7)-PIM and AGS
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Beers criteria] represent the most known and most comprehensive tools in the US and Europe today, applicable in regulatory studies. Because the STOPP/START criteria require for identification of PIMs the data on clinical conditions of medication use in an individual patient (lab values and results of other clinical assessments), they were not applicable in our research. 6 The AGS 2015 Beers criteria (Section 1) and EU(7)-PIM list were mostly used because potential inappropriateness of PIMs according to these criteria was defined mostly by medication-related characteristics (e.g. limits of a single dose, retard and nonretard drug forms, route of application, etc.). The 2015 AGS Beers criteria consisted of four sections and of those only Section 1 (PIMs mostly independent on clinical conditions) was selected for our research. 4 The EU(7)-PIM criteria stated mostly PIMs independent of diagnoses and other clinical conditions (with a few exceptions) 6 and all items were included in analyses [e.g. disregarding the length of the treatment and several disease-related conditions for a few PIMs (on both lists) to use as extensive methodology as possible].
Focus of our analyses was mainly on approval rates of PIMs (with regard to or not including specific medication-related conditions of inappropriateness; and on actually marketed PIMs (see Figure 1 in the Results section), and their availability on prescription or also as OTC drugs (see Figure 3 in Results section). With regard to medicationrelated conditions of inappropriateness, we conducted evaluation of all approved brand names, drug forms and doses in individual countries. However, our intention was not to focus on comparisons of all relative contraindications, specific warnings for the geriatric population, and clinical conditions defining appropriate/inappropriate use of PIMs in the summary product characteristics (SPCs) because such study would require a huge effort of international expert teams and merits more extensive and specifically developed methodology. Considering the huge number of brand names of PIMs approved by national authorization procedures in different countries (different drug forms, doses, etc.), even our analyses comparing approval rates of PIMs, their marketing, and availability only on prescription or as OTC drugs required substantial effort and is exceptional in the scientific literature. We also studied qualitative differences in approval rates of PIMs, means differences in PIMs withdrawn from the pharmaceutical markets by regulatory agencies between 2016 and 2018, and newly approved for clinical use in this period. We also searched which PIMs from the total list were approved by the central authorization procedure of the EMA.
Primary data for our study were collected between September and December 2016 and checked and corrected during spring 2017. Problematic areas were discussed during face-toface meetings in the period 2016-2018, and last check and corrections of data were conducted in autumn 2018 (before first submission of our research paper) and during the first revisions in February-March 2019. Information was obtained from official websites of national drug-regulatory institutes [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] and verified by national research teams using national drug compendia, national drug formularies, reimbursement compendia, or using opinions of experts from national regulatory institutes. Country-specific research teams recorded all necessary information (see Table 1 ) and this was checked twice by two independent researchers. 31-51
Data summary and statistical analyses
We used descriptive statistical methods to express quantitative differences in approval rates of PIMs in participating countries for 2018 year. Results of quantitative analyses were summarized in graphs presenting differences in approval rates of PIMs in participating EU countries using EU (7)-PIM list and 2015 AGS Beers criteria (comparing approved and currently marketed PIMs, as well as results obtained regarding or not including conditions of inappropriateness of PIMs; see Figure 1 ). Also another graph has been created to document absolute numbers of PIMs approved for clinical use in individual countries using EU (7)-PIM list and AGS 2015 Beers criteria based on the Anatomic Therapeutic Chemical (ATC) Classification System (again, both regarding and not including conditions of PIM inappropriateness, see Figure 2 ). We also documented percentages of marketed PIMs available only on prescription or as OTC medications (see Figure 3 ).
In the summary tables, we described changes in PIMs approved for clinical use on different pharmaceutical markets between 2016 and 2018 (see Table 3 , newly approved PIMs and PIMs
journals.sagepub.com/home/taw 5 AGS, American Geriatric Society; ATC, Anatomic Therapeutic Chemical Classification System; PIM, potentially inappropriate medication.
withdrawn from the pharmaceutical market in individual countries) and characteristics of PIMs approved for clinical use in only one of six analyzed countries (see Table 4 ). Also, percentages of PIMs approved by the central authorization procedure of the EMA have been expressed and stated in the text in the Discussion section.
All charts were made using R software (version 3.5.1). The differences in the proportion of PIMs approved for clinical use on pharmaceutical markets according to the EU (7)-PIM list and 2015 AGS Beers criteria were stated using percentages. Differences in results over 5% were considered substantial.
In order to describe and appropriately comment on main differences between regulatory systems in different countries, we created Table 2 that describes the total number of inhabitants, proportion and absolute number of seniors in the population in individual countries, number of approved medicinal products, brand names and active substances, types of medicine authorization procedures and responsible national institutions, as well as selected information on specific educational programs or guidelines helping to increase knowledge about PIMs and regulate PIM use at a national level (see references ). Table 2 shows the differences in main characteristics among participating countries: the size of total and senior population, medicines marketing authorization procedures, national responsible institutions, and availability of medication safety and educational strategies or guidelines related to PIMs in individual countries. In relation to the areas described in Table 2 , major differences were found in the size of total population (the largest country was TR with over 74 million inhabitants, and the second largest, ES, with more than 46 million inhabitants), in the proportion of older adults in the population (7.3% in TR compared with 15.8-19.0% in other countries), and in lower numbers of registered active substances in TR and RS (see Table 2 ). Figure 1) . Apart from conditions of PIM inappropriateness, results yielded nearly the same prevalence (difference was maximally 1.1% for all outputs, see Figure 1 ). Figure 2 ). These absolute numbers for EU (7) In CZ (n = 6) and TR (n = 21), the highest absolute number of PIMs were approved for clinical use in this period, while in other countries, this number was lower (<4). The highest absolute number of PIMs were withdrawn from pharmaceutical markets in RS (n = 10), TR (n = 8), and HU (n = 5; in other countries these were only a few PIMs, <3; see Table 3 ).
Results
Qualitative analyses discovered some PIMs that have been approved in only one of six analyzed EU countries and may be considered 'unnecessary' (see Table 4 ). The majority of these PIMs have been approved for clinical use in TR (n = 14), but some of these PIMs (n = 8) have not been marketed for a long time (see Table 4 ). More PIMs have been also specifically available on pharmaceutical markets in ES (n = 12), and PT (n = 6). In CZ and HU, there was only one PIM each (dihydroergotoxine and zaleplon, respectively). For more information, refer to 
Discussion
Our study is the first study analyzing in detail crosscountry differences in approval rates of PIMs, their actual marketing and availability on prescription or as OTC medications. We also analyzed longitudinal changes in PIM approval rates between 2016 and 2018 (withdrawals from the pharmaceutical markets and new approvals) in six European countries, taking part in the scientific works of the EU COST Action IS1402 WG1b research group. These were ES and PT (long-term member states of the EU), CZ and HU (short-term EU member states), and TR and RS (EU-candidate countries). The aim of our research was to analyze qualitative and quantitative differences in the lists of PIMs approved for clinical use and marketed in these countries, to describe selected differences in regulatory aspects related to PIM approvals, marketing and availability that should be harmonized and better regulated in future decades.
We chose for our analyses two latest EU-and US-explicit criteria of PIMs, namely the EU(7)-PIM list (European tool representing the most comprehensive explicit list of PIMs developed for international European research) 7 and the AGS 2015 Beers criteria (at the time of our analyses, the latest and the most comprehensive tool in the US from which only the Section 1 was applicable in our regulatory analyses). 4 Results of our analyses confirmed that PIMs stated on the EU(7)-PIM list were approved for clinical use in participating EU countries more often than PIMs stated in AGS 2015 Beers criteria (approval rates ranged for EU(7)-PIM list from 42.4% in RS to 70.7% in ES and for AGS Beers 2015 Criteria from 36.4% in RS to 64.3% in ES, respectively, with regard to the conditions of PIM inappropriateness). Only in TR, differences between the two analyzed criteria were not substantial, which means lower than 5%.
In agreement with our findings, several epidemiological studies in Europe confirmed that PIM prevalence with the EU(7)-PIM list was higher than after application of 2015 AGS Beers criteria. For example, the German study in community-dwelling older patients identified 37.4% PIM users after application of the EU(7)-PIM list and only 26.4% according to AGS Beers 2015 criteria, with longitudinal decrease in 6 years to 36.5% and 23.1%, respectively. 52 In Lithuania, the study of Grina and colleagues analyzed medication claim data in older outpatients and confirmed that application of the EU(7)-PIM list documented the prevalence of 57.2%, while by the application of the AGS Beers 2015 criteria the prevalence was only 25.9%. 53 Also in TR (a European-Asian country), the prevalence of PIM use was found to be 30% after application of the AGS Beers 2015 criteria in community-dwelling older patients, 54 and 65% when the EU(7)-PIM list was applied in the outpatient setting. 55 Even if both the EU(7)-PIM list and AGS Beers 2015 criteria have been developed for international research purposes, the EU(7)-PIM list identifies higher PIM prevalence in European countries. However, results of PIM prevalence can be of course influenced by many other factors, for example, preferences in PIM use, regulatory measures, etc.
Moreover, the AGS Beers 2015 criteria include more PIMs defined by clinical conditions of inappropriateness; 51, 52 for instance, the comparison of the AGS Beers 2015 criteria and STOPP version 2 criteria in the clinical setting in one Spanish study yielded nearly the same and very high prevalence, almost 70%, 56 which confirms that these tools may also be highly applicable in clinical studies in EU countries. Also, our results were influenced by the fact (see Figure 2 ) that a significantly lower number of PIMs was stated in Section 1 of the AGS Beers 2015 criteria in comparison with the EU(7)-PIM list.
Considering the countries participating in our research, the highest approval rates of PIMs were demonstrated in ES (70.7% of PIMs regarding medication-related conditions of inappropriateness and 71.4% not including conditions of PIM inappropriateness). This is in agreement with the fact that ES was the only country involved in the development of the EU(7)-PIM list 7 and we discovered during our analyses that many specific PIMs from the EU(7)-PIM list were approved only on the Spanish pharmaceutical market. Higher prevalence of approved PIMs was also documented in PT and TR (according to the EU(7)-PIM list, 67.1% and 67.5%, respectively, not including conditions of inappropriateness). While similar results in PT and ES can be explained by similarities between Spanish and Portuguese pharmaceutical markets, in TR, these findings are most likely more influenced by different drugregulatory measures. 57 TR and RS are not EU member states, only EU-candidate countries; therefore, granting marketing authorization to medical products through the centralized authorization procedure
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of the EMA or other EU authorization procedures (see Table 2 and the Introduction) are not applied. Even if licensing processes in both of the countries are now harmonized with EU legislation, national authorization procedures still dominate. 57 Table 2 shows that national authorization procedures in these countries contribute to lower availability of active substances, and in the case of RS, also to lower availability of PIMs. This is fairly different in TR, where the prevalence of approved PIMs was high, and also the total number of registered medicinal products was the highest (see Table 2 ), as well as the variability of different approved brand names, strengths, and drug forms of PIMs. According to the article of Oner and colleagues, the EMA, US Food and Drug Agency and Turkish Medicines and Medicinal Devices Agency apply different regulatory measures and different authorization procedures, and are autonomous in their decisions. 57 Many PIMs listed in Table 3 are approved only on the Turkish pharmaceutical market, not in other EU countries. However, some of these PIMs are not marketed anymore (e.g. acepromazine, belladonna alkaloids, buclizine, carbinoxamine, chlordiazepoxide, etc.) This could also mean that TR as an EU-candidate country (the opposite of RS) still does not fully apply the rule of EU legislation called the 'sunset clause,' a legal provision stating that the marketing authorization of a medicine will cease to be valid if the medicine is not placed on the market within 3 years of the authorization being granted or if the medicine is removed from the market for 3 consecutive years. [25] [26] [27] In agreement with these findings, TR was the country in our sample with the highest discrepancies between approved and actually marketed PIMs (the difference was 19.8% for the EU(7)-PIM list and 21.7% for AGS Beers 2015 criteria), in other countries, these differences were not substantial. Also, the highest number of PIMs without prescription was available in TR [over 45% using EU (7) or AGS Beers 2015 criteria, compared with less than 18% in other EU countries]. On the other hand, in RS, EU rules were followed more closely and according to local experts from the Medicines and Medicinal Devices Agency of RS, lower numbers of registered medicinal products in this country also highly contributed to the generally lower number of approved PIMs.
In Central and Eastern EU countries (CZ, HU and RS), specificity of the EU (7) 59 it was emphasized that '…strict regulations, including regulation of drug authorization and reimbursement approaches, can be put in place only for a small number of medications that are "particularly harmful or have few reasonable indications" and most of the PIMs on the list are not absolutely but potentially inappropriate (as they could be appropriate for some patients or certain clinical circumstances) and strict regulations could limit patients' access to beneficial therapy. ' We can only partially agree with this statement. Our analyses confirmed that some PIMs are no more needed in many EU countries and are still approved and used on some country-specific pharmaceutical markets (see Table 4 
Study limitations
The main limitation of our study is that it has been conducted in only six European countries and results cannot be simply extrapolated to other EU countries (considering all qualitative and quantitative differences). Thus, before application of our results and the EU(7)-PIM list to other conditions, all discrepancies should always be thoroughly described. The number of PIMs Therapeutic Advances in Drug Safety 10 evaluated in this study by the EU(7)-PIM criteria was twice higher than stated in the AGS 2015 Beers criteria (Section 1), and this fact also substantially contributed to differences in approval rates of PIMs using both methodologies. Because the aim of our study was not to describe in detail all different regulatory measures in participating countries, this issue must be thoroughly studied in other research projects. Also, we have to emphasize that, even if no dramatic changes in approval rates of PIMs have been found in the majority of countries between 2016 and 2018, all data presented have a time-dependent effect. New drugs are continuously approved on, and withdrawn from, different pharmaceutical markets, and our report might become out of date soon, particularly when it stimulates future positive changes in regulatory measures regarding PIMs' availability in participating countries.
We would like to highlight that regulatory measures related to PIMs (even if they are very powerful) are only one of the strategies in the whole puzzle of interventions that may be useful in improving rational drug prescribing in older patients. More-over, some PIMs can be still used appropriately for some specific indications, also in geriatric patients. But, regulations of 'always unnecessary and risky PIMs' were found very beneficial [with regard to regulation of activesubstance availability, approved drug doses in drug forms (e.g. in one tablet), or limitation of prescription of PIMs by prescribers not having relevant postgraduate specialty, etc.]. With respect to the fact that some PIMs do not have already a place in prescribed drug regimens in older patients, stronger regulations must be approved for those PIMs, where only 'historical prescribing habits' play a role in their continuous prescribing. In such cases, regulatory measures may present a powerful strategy for how to stop inappropriate use of these PIMs in older patients.
Conclusion
The EU(7)-PIM list has been created for international European research; however, applicability of these criteria in many EU countries is still limited because different PIMs are available on different European pharmaceutical markets, and additional PIMs not listed by these criteria have not been yet identified in many EU countries. High specificity of these criteria was determined for the pharmaceutical market of a country that contributed to the development of the EU(7)-PIM list (ES), low specificity in Eastern and Central EU countries, where more research effort is needed in this area.
Moreover, the lack of evidence on PIM prescribing in older patients in different settings of healthcare, particularly in Central and Eastern Europe, contributes to probably still higher rates of inappropriate prescribing of PIMs in many countries, regions and healthcare facilities. As the area of PIMs is one of very important areas for deprescribing strategies in older patients using polypharmacy, regulatory measures and specific aspects of PIM use should gain more interest (of prescribers, educators, and drug-regulatory institutions). The European project EUROAGEISM H2020, FIP7 program (2017-2021), focusing on problems related to PIM use in Central and Eastern Europe with a special focus on aspects of PIM prescribing and relevant regulatory measures, could help to obtain new evidence stimulating the significant change in PIM availability and use in this European region.
